Efmody 10 mg modified release hard capsules ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
81先天性副腎皮質酵素欠損症1

81. 先天性副腎皮質酵素欠損症


臨床試験数 : 87 薬物数 : 87 - (DrugBank : 23) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 68
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-004467-26-FR
(EUCTR)
09/12/2021An Open-label Extension Study to Evaluate the Long-term Safety andTolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal HyperplasiaA Phase 3 Open-label Extension Study to Evaluate the Long-term Safety andTolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal Hyperplasia Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: Efmody 5 mg modified release hard capsules
Product Name: Chronocort 5mg
INN or Proposed INN: HYDROCORTISONE
Other descriptive name: HYDROCORTISONE MICRONIZED
Trade Name: Efmody 10 mg modified release hard capsules
Product Name: Chronocort 10mg
INN or Proposed INN: hydrocortisone
Other descriptive name: HYDROCORTISONE MICRONIZED
Diurnal LimitedNULLNAFemale: yes
Male: yes
181Phase 3United States;France;Japan